Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Colorectal Neoplasms Clinical Trial

Official title:

An Uncontrolled, Open-label Phase IIb Trial of Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02465502
• Other study ID #: 17217
• Status: Completed
• Phase: Phase 2
• Start date: July 21, 2015
• Est. completion date: December 11, 2017

Study information

• Verified date: November 2018
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the efficacy (as measured by progression-free survival [PFS] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never exposed to antiangiogenic therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: December 11, 2017
• Est. primary completion date: May 2, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female subjects =18 years of age;

• Histological or cytological confirmation of adenocarcinoma of the colon or/and rectum;

• Subjects with metastatic colorectal cancer (CRC) whose disease progressed or who were intolerant to standard chemotherapy based on fluoropyrimidine, oxaliplatin, irinotecan, and an anti-EGFR therapy if RAS wild-type. This progression must be during or within 4 months following the last administration of standard therapies.

• Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, Version 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate bone-marrow, liver, and renal function

• Women of childbearing potential and men must agree to use adequate contraception when sexually active during the study and for at least 8 weeks after the last study drug administration.

Exclusion Criteria:

• Prior treatment with an antiangiogenic agent;

• Congestive heart failure of New York Heart Association (NYHA) class 2 or worse;

• Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study drug;

• Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

• Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic pressure >90 mmHg despite optimal medical management);

• Ongoing acute or chronic infection (> Grade 2 NCI-CTCAE v 4.03);

• Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication) events within 6 months of study enrollment. Subjects being treated with low-weight heparin are allowed to participate as long as dose is limited to prophylactic use.

• Any history of or currently known brain metastases (head CT/MRI will be performed during screening period if brain metastases are suspected)

• Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years before study entry, except for curatively treated cervical cancer in situ, in situ ductal breast cancer, non-melanoma skin cancer and superficial bladder tumors;

• Last chemotherapy dose or any other anti-cancer therapy administered in less than 4 weeks from start of study treatment;

• Use of therapeutic anticoagulation;

• Proteinuria > 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.03) on urinalysis screening result. If there is medical history of proteinuria, previous urinalysis results should be considered and/or performed so at least 2 results separated by at least 2 weeks are available;

• History of interstitial lung disease with ongoing signs and symptoms at the time of informed consent;

• Non-healing wound, non-healing ulcer, or non-healing bone fracture;

• Subjects with evidence or history of any bleeding diathesis, irrespective of severity;

• Any hemorrhage or bleeding event = Grade 3 NCI-CTCAE v 4.03 within 4 weeks prior to the start of study medication;

• Known history of human immunodeficiency virus (HIV) infection;

• History of active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy;

• Pregnancy or breastfeeding.

Related Conditions & MeSH terms

• Colorectal Neoplasms

Intervention

Drug:
• Regorafenib (Stivarga, BAY73-4506)
Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants without disease progression or death at the end of 8 weeks		At week 8
Secondary	Progression-Free Survival (PFS)	PFS is defined as the date from the first dose of regorafenib until radiologic and/or clear clinical progression or death from any cause, whichever comes first.	Approximately 2 months
Secondary	Overall Survival (OS)	OS is defined as the date from the first dose of regorafenib until death by any cause.	Approximately 2 months
Secondary	Overall Response Rate (ORR)	ORR is defined as the proportion of subjects with the best tumor response (confirmed PR or CR) that is achieved during or within 30 days after therapy.	Approximately 2 months
Secondary	Disease Control Rate (DCR)	DCR is defined as the proportion of subjects who have a best response rating over the whole duration of the study of CR, PR, or SD.	Approximately 2 months
Secondary	Metabolic response measured by [18F] fluorodeoxyglucose positron emission tomography (FDG PET)		Approximately 2 months
Secondary	Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03		Approximately 2 months

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer products.